aibioChina Resources Pharmaceutical unit issues RMB2 billion corporate bonds
Tickers 3320
A non-wholly owned subsidiary completed the third tranche of its 2026 corporate bonds, RMB2 billion at 1.59% per annum over three years.
Key facts
- Company
- China Resources Pharmaceutical Group Ltd. (HKEX: 3320)
- News type
- Debt Financing
- Primary source
- China Resources Pharmaceutical Group Limited announcement (2026-06-26)
China Resources Pharmaceutical Group Limited said on June 26, 2026 that CR Pharmaceutical Commercial, a non-wholly-owned subsidiary, completed a public issuance of the third tranche of its 2026 corporate bonds in the PRC. The announcement refers to earlier announcements dated 27 March 2026 and 28 April 2026 about the first and second tranches.
The third tranche was issued in a principal amount of RMB2 billion. The bonds have a term of three years and a coupon rate of 1.59% per annum.
The net proceeds will be used for production expenditures, including replenishment of working capital, repayment of interest-bearing debts, project investments and other purposes that comply with applicable laws and regulations.
The announcement names no underwriter, placement agent or advisor for the tranche. Shareholders and potential investors were told to take care when dealing in the company's securities. The announcement was issued by order of the board and signed by the chairman, Mr. Bai Xiaosong.